Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
Sign Up to like & getrecommendations! Published in 2022 at "Blood Cancer Journal"
DOI: 10.1038/s41408-022-00618-4
Abstract: Dear Editor, Signaling downstream of the pathogenetic mutations in JAK2, MPL, or calreticulin, along with co-occurring mutations in chromatin modifiers or transcription factors, results in dysregulated transcriptome and proteome that is responsible for the transformation… read more here.
Keywords: mpn saml; bay 1143572; treatment; post ... See more keywords
Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-130783
Abstract: LSD1 (KDM1A) is an FAD-dependent amine-oxidase that demethylates mono and dimethyl histone H3 lysine 4 (H3K4Me1 and H3K4Me2), which regulates active enhancers and transcription in AML stem/progenitor cells (LSCs). LSD1 is part of the repressor… read more here.
Keywords: mpn saml; post mpn; research; research funding ... See more keywords